Cellular and Molecular Pathways of Neurotoxicity: Relevance to Neurodegenerative Diseases
Chair:  Jean L. Cadet
(Sponsored by the Divisions for Toxicology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Drug Discovery, Drug Development & Regulatory Affairs; and Systems & Integrative Pharmacology)
Room:  Moscone 307

Alteration in mitochondrial membrane proteome and oxidative damage in MPTP-induced Parkinsonian models
  Syed F. Ali, National Center for Toxicological Research/FDA

Iron dysregulation and neurodegeneration: Cause or consequence?
  Julie  K. Anderson, Buck Institute for Aging Research

Amphetamine-induced neuronal apoptosis:  Novel observations
  Irina N. Krasnova, National Institute of Drug Abuse, NIH

Microglial activation as a specific marker for neurotoxicity
  Donald M. Kuhn, Wayne State University

Molecular bases of methamphetamine-induced neurodegeneration in the striatum
  Jean L. Cadet, National Institute of Drug Abuse, NIH

THERE WILL BE A POSTER SESSION ON THE RELEVANCE OF CELLULAR AND MOLECULAR PATHWAYS OF NEUROTOXICITY TO NEURODEGENERATIVE DISEASE IN THE EXHIBIT HALL FOLLOWING THIS SYMPOSIUM.

Ray Fuller Symposium
Signal Transduction:  Relevance to CNS Disorders and Therapeutic Approaches
Chair:  Marc G. Caron
Room :  Moscone 303

Signaling pathways that underlie behavioral alternations in neurological disorders
   Li-Huei Tsai, Harvard Medical School 

5HT2A receptor signaling and hallucinogen action: Implication for the therapy of psychotic disorders
  Jay A. Gingrich, Columbia University College of Physicians and Surgeons

The yin and yang of 5HT2A receptor signaling: Caveolin and RSK-2
  Bryan L. Roth, Case Western Reserve University

Targeting of signal transduction mechanisms for therapeutic benefits
  Husseini Manji, NIMH, NIH

Metabotropic Glutamate Receptors
Chairs:  Michael F. O'Neill and Nick Moore
(Sponsored by the Divisions for Behavioral Pharmacology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Drug Discovery, Drug Development & Regulatory Affairs; Neuropharmacology; and Systems & Integrative Pharmacology
Room :  Moscone 309

Molecular pharmacology of metabotropic glutamate receptors
  Michael P. Johnson, Lilly Research Laboratories

The role of group II metabotropic glutamate receptors in cognition
  Theresa M. Ballard, Hoffman-La Roche AG, Basel, Switzerland

Metabotropic glutamate receptors in substance abuse
  Linda M. Rorick-Kehn, Eli Lilly & Company

Metabotropic glutamate mechanisms in anxiety
  Robert Hodgson, Schering Plough Research Institute

Summation: Achievements and challenge
  Michael F. O’Neill, Eolas Biosciences, Ltd., London

Imaging Modalities that Bridge Preclinical and Clinical Drug Efficacy
Chairs:  Bryan F. Cox and Darrell R. Abernethy
(Sponsored by the Divisions for Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Drug Discovery, Drug Development & Regulatory Affairs; and Systems & Integrative Pharmacology)
Room:  Moscone 301

fMRI of the brain: Utility in assessment of drug targets
  Stephen M. Rao, Medical College of Wisconsin & Neurognostics, Inc., Milwaukee

Molecular imaging with PET/SPECT in drug design and development
  Dean F. Wong, Johns Hopkins University School of Medicine

Echocardiography for assessment of cardiac and vascular function:  Role in assessing drug effects
  Jane E. Freedman, Boston University School of Medicine

Imaging bone and joint disease in the evaluation of drug effect: Insight into ultrastructural changes by microCT and infrared imaging 
  Nancy P. Camacho, Hospital for Spec. Surgery, New York

In vivo NMR:  Role in phenotyping of transgenic disease models
  Richard Spencer, National Institute of Aging, NIH

Embryonic Stem Cell Therapy: From Cardiogenesis to Heart Repair
Chair:  Andre Terzic   
(Sponsored by the Divisions for Cardiovascular Pharmacology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Molecular Pharmacology; and Systems & Integrative Pharmacology)
Room:  Moscone 305

Remarks by chair.
  Andre Terzic, Mayo Clinic

Rescue of cardiac defects with embryonic stem cells
  Diego Fraidenraich, Sloan-Kettering Cancer Institute 

Embryonic stem cells: Guided cardiogenesis for safe repair
  Atta Behfar, Mayo Clinic 

Human embryonic stem cells: Promise for cardioregenerative medicine
  Timothy J. Kamp, University of Wisconsin Medical School, Madison

Stem cells: Application in clinical practice
  Nabil Dib, Arizona Heart Institute, Phoenix

Best Practices in Pharmacology Education
Chair:  Jordan E. Warnick
(Sponsored by the Division for Pharmacology Education)
Room:  Moscone 302

Principles of best practices in medical education – How do we meet standards?
  Jordan E. Warnick, University of Maryland School of Medicine

Applied learning in pharmacology
  John L. Szarek, Ross University School of Medicine

Construction of exam questions: Relationship to learning objectives and board examinations
  Jack W. Strandhoy, Wake Forest University School of Medicine

The classroom as stage
  Ann Woodworth, Northwestern University, Evanston, IL

vUsing Genetic Approaches to Define the Role of Adenosine in the Cardiovascular System
Chair:  John A. Auchampach
(Sponsored by the Divisions for Cardiovascular Pharmacology; Molecular Pharmacology; and Systems & Integrative Pharmacology)
Room :  Moscone 305

Role of A1 adenosine receptors in regulating kidney function
  Jurgen B. Schnermann, National Institute of Diabetes, and Digestive and Kidney Diseases, NIH

Role of A2A adenosine receptors in tissue injury
  Joel Linden, University of Virginia

A3 adenosine receptors and cardiac protection
  John A. Auchampach, Medical College of Wisconsin

Phenotypic characterization of A2B adenosine receptor gene "knock-out"mice
  Katya Ravid, Boston University School of Medicine

* Agonists of the A2A adenosine receptor reduce inflammation and hypoxia-induced pulmonary damage in transgenic sickle cell mice.
    Kori Wallace, University of Virginia

* Characterization of expression and function of adenosine receptors in mouse neutrophils
    Dharini van der Hoeven, Medical College of Wisconsin

¯ Junior speaker chosen from meeting abstracts

Preclinical Models for Cognitive Enhancers: Within Reach or Still Too Great a Stretch?
Chairs:  Gary S. Lynch and Kathleen M. Kantak
(Sponsored by the Divisions for Behavioral Pharmacology; Drug Discovery, Drug Development & Regulatory Affairs; Neuropharmacology; and Systems & Integrative Pharmacology) 
Room:  Moscone 309  

Will cognitive enhancers arrive in the clinic before we have preclinical tests for them?
  Gary S. Lynch, University of California, Irvine

Valuation and decision-making in primate brain
  William T. Newsome, Stanford University School of Medicine

Recollection-like memory retrieval in rats
  Norbert Fortin, Boston University

Cognitive enhancers and the trace reactivation theory of memory consolidation
  Bruce McNaughton, University of Arizona

A skeptical look at the prospects, near term at least, for cognitive enhancement
  Richard G.M. Morris, University of Edinburgh         
 

Targets of Toxicant Sensitivity in Aging
Chair:  Harihara M. Mehendale
(Sponsored by the Divisions for Toxicology; Drug Metabolism; and Systems & Integrative Pharmacology)
Room:  Moscone 303

Age related molecular mechanisms of acute renal failure
  Alan R. Parrish, Texas A&M Univ

Aging protects against chlordecone amplified progression of haloalkane hepatotoxicity
  Harihara M. Mehendale, Univ. of Louisiana Sch of Pharmacy

Aging and sensitivity to organophosphorus insecticides:  Toxicokinetic and toxicodynamic factors 
  Carey Pope, Oklahoma State Univ

An association between extended lifespan and elevated xenobiotic metabolism is revealed through gene expression studies 
  Gretchen J. Darlington, Baylor College of Medicine

Biotransformation and  Drug Transport:  Drug Metabolism Platform Session
Chairs:  David S. Riddick and Laurence S. Kaminsky
(Sponsored by the Division for Drug Metabolism)
Room:  Moscone 307

Division for Pharmacology Education Symposium:  Distance Education in Pharmacology: Promises and Pitfalls
Chair:  Patangi K. Rangachari
Room:  Moscone 301

Delivering the Pharm.D. curriculum through distance education
  Mary L. Euler, University of Missouri School of Pharmacy, Kansas City

Medical school by Internet?  What's possible, what's not
  Patricia B. Williams, Eastern Virginia Medical School

Knowledge management in a learning organization
  Hans-Juergen Roethig, Phillip Morris USA, Richmond

On-line problem-based learning: Action at a distance for undergraduate science students
  Patangi K. Rangachari, University of Calgary   

Monday Afternoon (3:00 pm - 5:30 pm)

Division for Behavioral Pharmacology Session:  Behavioral Pharmacology at Fifty:  A Look to the Future
Chairs:  Carol A. Paronis and Linda Dykstra
Room:  Moscone 303

Effects of antipsychotics in inbred mice: A confluence of pharmacology, genetics, and behavior
  Todd L. McKerchar, University of Kansas

Studying a “dirty” drug: Using drug discrimination procedures to identify mechanism of action
  Larry P. Carter, Johns Hopkins University School of Medicine

Antidepressant-like effects of delta-opioid agonists
  Emily M. Jutkiewicz, University of Michigan Medical School

MDMA is plural: in vivo pharmacology of the racemate in comparison with its component isomers
  Bill E. Fantegrossi, Emory University

Dopamine transporter ligands as potential cocaine antagonists: Contribution of in vivo rate of occupancy at the dopamine transporter
  Rajeev I. Desai, NIDA, NIH

Behavioral pharmacology at 50
  Alice M. Young, Texas Tech University Health Science Center

 

Division for Drug Discovery, Drug Development & Regulatory Affairs Symposium: Innovative Drug Delivery Strategies:  Knocking on the Door of Drug Development
Chair:  Tom C. Stover
Room:  Moscone 301

Keynote Talk: Novel medical aerosol research toward new treatments of infectious disease
  David A. Edwards, Harvard University

Targeting drugs to the vascular endothelium
  Vladimir Muzykantov, University of Pennsylvania School of Medicine

Controlled delivery technology to the peripheral and central nervous systems
  Daniel S. Kohane, Massachusetts General Hospital

Antitumor drug delivery using dendrimers and liposomes
  Francis C. Szoka, Jr., UCSF

Division for Drug Metabolism Symposium:  Metabolomic/Metabonomic Probes of Drug Metabolism Consequences

Chair:  Larry S. Kaminsky
Room:  Moscone 307

Understanding mechanisms of drug toxicity using UPLC coupled to time-of-flight mass spectrometry
  Robert S. Plumb, Waters Corporation

Application of human metabolomics to understanding dietary influences on drug metabolism
  J. Bruce German, University of California, Davis

Metabonomic-based probes of the effects of drug metabolism
  Hector C. Keun, Imperial College, London

Metabonomic-based probes of ranitidine idiosyncratic hepatoxicity
  Jane F. Maddox, Michigan State University

Division for Systems & Integrative Pharmacology Symposium:  Pharmacology of Cytokines in the Cardiovascular System
Chair:  R. Clinton Webb and Michael W. Brands
Room:  Moscone 305

Introduction
  R. Clinton Webb, Medical College of Georgia        

Role of cytokines in flow-induced vascular remodeling
  Vyacheslav A. Korshunov, University of Rochester

Tumor necrosis factor-alpha modulates the pressor activity of angiotensin II
  Joseph Francis, Louisiana State University, Baton Rouge

Interleukin-6 contributes to salt-sensitive hypertension
  Michael W. Brands, Medical College of Georgia

 Tumor necrosis factor-alpha and hypertension in response to reduced uterine perfusion
  Babbette LaMarca, University of Mississippi School of Medicine

v New Aspects of Glucocorticoid Signaling
Chairs:  Peter J. Barnes and Jeffrey S. Fedan
(Sponsored by the Divisions for Molecular Pharmacology and Systems & Integrative Pharmacology) 
Room:  Moscone 309

Glucocorticoid receptor structure and regulation
  John A. Cidlowski, National Institute of Environmental Health Science, NIH

Glucocorticoid effects on chromatin remodeling
  Peter J. Barnes, Imperial College, UK

Glucocorticoid effects on gene expression
  Keith R. Yamamoto, University of California, San Francisco

Novel glucocorticoid receptor ligands
  Jeffrey N. Miner, Ligand Pharmaceuticals

v Mood Stabilizers and Antidepressants: New Mechanisms for Old Compounds
Chair:  De-Maw Chuang 
(Sponsored by the Divisions for Neuropharmacology; Behavioral Pharmacology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Systems & Integrative Pharmacology; and Toxicology)
Room:  Moscone 307

Novel therapeutic applications for lithium and valproic acid
Peter S. Klein, University of Pennsylvania School of Medicine

Anti-apoptotic effects and therapeutic potentials of mood stabilizers for neurodegenerative diseases
  De-Maw Chuang, National Institute of Mental Health, NIH

Preclinical and clinical evidence for the trophic actions of mood stabilizing drugs
  Husseini Manji, National Institute of Mental Health, NIH

Contribution of hippocampal neurogenesis to behavioral effects of antidepressants
  Rene Hen, Columbia University Medical Center

Function, Regulation, and Genetic Polymorphisms of the Cytochrome P450 Reductase
Chair:  Xinxin Ding
(Sponsored by the Divisions for Drug Metabolism; Drug Discovery, Drug Development & Regulatory Affairs; and Systems and Integrative Pharmacology)
Room:  Moscone 301

In vivo Function of P450 reductase-dependent enzymes in mutant mouse models
  Xinxin Ding, New York State Dept of Health

Developmental function and regulation of P450 reductase
  Anna L. Shen, University of Wisconsin-Madison

Mutant P450 oxidoreductase causes disordered steroidogenesis in human patients
  Walter L. Miller, University of California, San Francisco

How are NADPH-cytochrome P450 reductase and multiple cytochromes P450 organized in membranes?
  Wayne L. Backes, Louisiana State Univ Health Science Center

Cytochrome P450 Reductase: Other Pathways and Alternative Reductases
  Todd D. Porter, University of Kentucky
 

 v Role of COX-2 in the Regulation of Cardiovascular Function
Chairs:  Albert L. Hyman and Ben R. Lucchesi
(Sponsored by the Divisions for Cardiovascular Pharmacology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; and Systems & Integrative Pharmacology)
Room:  Moscone 305

COX inhibition and cardiovascular hazard
  Garret A. Fitzgerald, University of Pennsylvania

Regulation of macula densa function and renin secretion by COX-2
  Raymond C. Harris, Vanderbilt University Medical Center

Role of COX-2 in the pulmonary circulation
  Philip J. Kadowitz, Tulane University Medical Center

Role of renal medullary COX-2 in regulating blood pressure and the adaptation to dietary salt
  Matthew D. Breyer, Vanderbilt University Medical Center

Role of COX-2 in the coronary circulation
  Ben R. Lucchesi, University of Michigan Medical School

v Oxidative stress and cyclooxygenase-1 and 2 mediate the hyperresponsiveness of the smooth muscle of the femoral artery of streptozotocin-treated rats.
    Yi Shi, University of Hong Kong, Faculty of Medicine

      vA junior speaker selected from the meeting abstracts

 v Beginner’s Guide to Emerging Technologies in Drug Development
Chair:  Shiladitya Sengupta
(Sponsored by the Divisions for Systems & Integrative Pharmacology; Cardiovascular Pharmacology; Drug Discovery, Drug Development & Regulatory Affairs; and Pharmacology Education)
Room:  Moscone 303

Introduction
  Shiladitya Sengupta, Harvard Medical School

Glycomics:  The study of complex sugars in novel drug development
  Carlos Bosques, Massachusetts Institute of Technology

Transcriptome:  From gene arrays to drug targets in endothelial pathophysiology
  Cristin C. Print, University of Cambridge

Proteomics:  An emerging technology for drug development
  Thomas P. Conrads, National Cancer Institute, NIH

Genetically engineered mice in drug discovery
  Pradip Majumder, Merck Research Laboratories & Harvard Medical School

v Ultrasound microbubble delivery of Ca²⁺ signaling second messengers into bovine coronary arterial smooth muscle cells.
      Guo Zhang, Medical College of Virginia

  vA junior speaker selected from the meeting abstracts
 

v Allosteric Modulation of GPCRs: From Small Molecules to Accessory Proteins
Chairs:  Arthur Christopoulos and Bryan L. Roth
(Sponsored by the Divisions for Molecular Pharmacology; Drug Discovery, Drug Development & Regulatory Affairs; and Neuropharmacology) 
Room:  Moscone 305

The pros and cons of allosteric modulators of GPCRs
  Arthur Christopoulos, University of Melbourne

Allosteric modulation of mGluRs:  A paradigm for family C GPCRs?
  Michael P. Johnson, Lilly Research Labs

"GIPs" (GPCR interacting proteins) for 5-HT and mGLU receptors: Discovery and examples of functions
  Joel Bockaert, INSERM

Computational approaches for identifying allosteric and orphan binding sites
  Ruben Abagyan, Scripps Research Institute

vA multivalent ligand that bridges the orthosteric and allosteric sites of the muscarinic M₂ receptor.
     Tod Steinfeld, Theravance, Inc., So. San Francisco

     vSpeaker chosen from meeting abstracts

THERE WILL BE A POSTER SESSION ON ALLOSTERIC MODULATION OF GPCRS IN THE EXHIBIT HALL ON TUESDAY.

vMultiple Approaches to NGF Antagonism for Novel Pain Drugs
Chair:  Franz F. Hefti 
(Sponsored by the Divisions for Neuropharmacology; Behavioral Pharmacology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Drug Discovery, Drug Development & Regulatory Affairs; and Systems & Integrative Pharmacology) 
Room:  Moscone 307                             

Introduction
  Franz F. Hefti, Rinat Neuroscience Corp.

NGF mediates pain sensation in the adult
  Lorne M. Mendell, State University of New York, Stony Brook

Peptibody NGF antagonists
  Kenneth D. Wild, Amgen, Inc.

NGF in cancer pain mechanisms
  Patrick W. Mantyh, University of Minnesota

Preclinical and clinical studies with anti-NGF antibodies in pain
  David L. Shelton, Rinat Neuroscience Corp.

vMammalian Nitric Oxide Metabolism and Signaling: Physiological and Therapeutic Frontiers
Chair:  David R. Janero
(Sponsored by the Divisions for Systems & Integrative Pharmacology; Clinical Pharmacology, Experimental Therapeutics & Translational Medicine; Cardiovascular Pharmacology; Drug Discovery, Drug Development & Regulatory Affairs; and Molecular Pharmacology)
Room:  Moscone 303

The unique nature of cell signaling by reactive nitrogen intermediates
  David A. Wink, National Cancer Institute, NIH

NObonomics: A metabonomics approach toward mapping global nitric oxide metabolism and signaling
  Martin Freelisch, Boston University School of Medicine

Assessing changes in the mitochondrial proteome in response to reactive nitrogen species
  Aimee Landar, University of Alabama at Birmingham

Nitrite anion as the biochemical HIF-1alpha: Role in physiology and therapeutics.
  Mark T. Gladwin, Clinical Center, NIDDK, NIH

vPeroxynitrite modulates the expression of Gi Protein and adenylyl cyclase signaling in vascular smooth muscle cells.
   Marcel Bassil, University of Montreal

vNitric oxide (NO) preconditioning protects endothelial cells against SNP-induced apoptosis via the hsp90-sGC pathway.
   Galina Antonova, Medical College of Georgia

   vJunior speakers selected from the meeting abstracts

THERE WILL BE A POSTER SESSION ON  MAMMALIAN NITRIC OXIDE METABOLISM AND SIGNALING IN THE EXHIBIT HALL ON TUESDAY.

Response to Oxidative Stress by Specific Epithelial Cell Types
Chair:  Philip R. Mayeux
(Sponsored by the Divisions for Toxicology and Systems & Integrative Pharmacology) 
Room:  Moscone 301

Oxidative stress in renal epithelial cell injury following ischemic injury
  Lee Ann MacMillan-Crow, University of Arkansas for Medical Science

Epididymal epithelium utilizes multiple strategies to protect itself from oxidative stress
  Barry T. Hinton, University of Virginia

Role of glutathione efflux pathways in lung epithelium and oxidative stress
  Brian J. Day, National Jewish Medical and Research Center

Determinants of intestinal oxidative susceptibility:  Cellular redox and cell transition state
  Tak Yee Aw, Louisiana State University Health Sciences Center

Retinal pigment epithelium: Cell heterogeneity, culture density and oxidative stress
  Janice M. Burke, Medical College of Wisconsin

Monoclonal Antibody and Small Molecule Cancer Therapies - What's the Difference?
Chairs:  James D. Winkler and Lori S. Friedman
(Sponsored by the Divisions for Drug Discovery, Drug Development & Regulatory Affairs and Clinical Pharmacology, Experimental Therapeutics & Translational Medicine) 
Room:  Moscone 309 

Clinical development and opportunities for Tarceva (erlotinib), a small molecule inhibitor of the EGF receptor
  Lee D. Arnold, OSI Pharmaceuticals  

Uses and limitations of Erbitux (cetuximab), an antibody inhibitor of the EGF receptor
  Zhenping Zhu, ImClone Systems, Inc.

Clinical development of Avastin (bevacizumab), an anti-VEGF antibody. 
  Robert D. Mass, Genentech, Inc   

Uses of Vatalanib (CPG-79787), a small molecule inhibitor of VEGF
  Amanda Littlewood-Evans, Novartis NIBR, Basel, Switzerland

Overview and critical perspectives on small molecule and antibody therapies  
  Paul Workman, Cancer Research UK